Nicotinic receptor agonists for the treatment of inflammatory diseases

Abstract

This invention relates to the use of nicotine receptor agonists for treating inflammatory diseases, including a variety of pulmonary diseases. Such agonists have fewer side effects than other anti-inflammatory drugs, such as steroids. Moreover, these agonists can be used alone or in combination with other anti-inflammatory drugs to alleviate pulmonary diseases.

1 . A method of treating pulmonary inflammation of an inflammatory disease selected from the group consisting of asthma, interstitial pulmonary fibrosis (IPF), sarcoidosis, hypersensitivity pneumonitis (HP), chronic HP and bronchiolitis obliterans with organizing pneumonitis (BOOP) in an animal in need thereof having said inflammation, comprising administering to said animal a nicotinic receptors agonist selected from nicotine and dimethylphenyl-piperazinium. 
   
   
       2 . The method as defined in  claim 1 , wherein said nicotinic receptors agonist is dimethylphenylpiperazinium (DMPP). 
   
   
       3 . The method as defined in  claim 1 , wherein said pulmonary inflammatory disease is asthma. 
   
   
       4 . The method as defined in  claim 1 , wherein said nicotinic receptors agonist is administered by oral, sublingual, intraperitoneal, intravenous, inhaled, intratracheal, intranasal, parenteral, topical, direct injection, infusion or intraocular administration. 
   
   
       5 . The method as defined in  claim 3 , further comprising administering at least one of bronchodilator, anti-inflammatory, antileukotriene or immunosuppressive agent. 
   
   
       6 . The method as defined in  claim 5 , wherein said at least one of bronchodilator, anti-inflammatory, antileukotriene or immunosuppressive agent is administered by oral, sublingual, intraperitoneal, intravenous, inhaled, intratracheal, intranasal, parenteral, topical, direct injection, infusion or intraocular administration. 
   
   
       7 . The method as defined in  claim 5 , wherein said nicotinic receptor agonist is dimethylphenylpiperazinium (DMPP). 
   
   
       8 . A method of treating bronchial or interstital inflammation from a pulmonary inflammatory disease selected from the group consisting of asthma, interstitial pulmonary fibrosis (IPF), sarcoidosis, hypersensitivity pneumonitis (HP), chronic HP and bronchiolitis obliterans with organizing pneumonitis (BOOP) in an animal in need thereof having said inflammation, comprising administering to said animal a nicotinic receptors agonist selected from nicotine and dimethylphenyl-piperazinium. 
   
   
       9 . The method as defined in  claim 8 , wherein said pulmonary inflammatory disease is asthma. 
   
   
       10 . The method as defined in  claim 9 , wherein said nicotinic receptor agonist is dimethylphenylpiperazinium (DMPP).